The immunotherapy for head and neck cancer
10.19401/j.cnki.1007-3639.2017.06.010
- VernacularTitle:头颈部肿瘤的免疫治疗
- Author:
Ye GUO
- Keywords:
Head and neck squamous cell carcinoma;
Immunotherapy;
Immune checkpoint inhibitor
- From:
China Oncology
2017;27(6):459-462
- CountryChina
- Language:Chinese
-
Abstract:
The predominant type of head and neck cancer is head and neck squamous cell carcinoma (HNSCC), which needs more effective treatment. As a highly immunosuppressive malignancy, HNSCC has 3 major mechanisms including induction of immune tolerance, local immune evasion, and disruption of T-cell signaling. Immune checkpoint plays a critical role in the function of T-cell and rapid development has been achieved by inhibiting programmed cell death 1 (PD-1). As anti-PD1 humanized monoclonal antibodies, pembrolizumab and nivolumab have proven to be effective in the salvage treatment for recurrent or metastatic HNSCC, further investigation is awaited.
